Insider Buying: AdaptHealth (NASDAQ:AHCO) Major Shareholder Buys $7,983,737.44 in Stock

AdaptHealth Corp. (NASDAQ:AHCO) major shareholder Richard Cashin, Jr. acquired 820,528 shares of AdaptHealth stock in a transaction on Tuesday, March 10th. The stock was acquired at an average cost of $9.73 per share, for a total transaction of $7,983,737.44. Following the purchase, the insider owned 14,638,708 shares of the company’s stock, valued at approximately $142,434,628.84. This represents a 5.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

AdaptHealth Stock Performance

Shares of NASDAQ:AHCO opened at $10.60 on Friday. The business has a fifty day moving average of $10.10 and a 200-day moving average of $9.68. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.81 and a current ratio of 1.02. AdaptHealth Corp. has a twelve month low of $7.11 and a twelve month high of $11.17. The firm has a market cap of $1.44 billion, a PE ratio of -19.27, a price-to-earnings-growth ratio of 1.22 and a beta of 1.76.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.34 by ($1.10). AdaptHealth had a positive return on equity of 3.42% and a negative net margin of 2.18%.The company had revenue of $846.29 million for the quarter, compared to analyst estimates of $832.51 million. During the same quarter last year, the company earned $0.34 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. On average, equities research analysts predict that AdaptHealth Corp. will post 0.88 EPS for the current fiscal year.

AdaptHealth News Roundup

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Major shareholder Richard M. Cashin Jr. executed multiple buys over March 10–12 totaling roughly 2.05 million shares (~$19.9M) at about $9.73/share, lifting his stake to ~15.86M shares — a strong insider vote of confidence that likely supported the rally. Investing.com article
• Positive Sentiment: Other filings and coverage show the same insider purchases (disclosed to the SEC) and note a multi-day, material increase in Cashin’s position — reinforcing the market interpretation of the buy as strategic accumulation rather than one-off trading. InsiderTrades article
• Positive Sentiment: Institutional activity shows selective buying (e.g., Goldman Sachs, UBS, new position from Woodline), which can add buying pressure and liquidity support. MarketBeat institutional note
• Neutral Sentiment: Analyst coverage is mixed — several “outperform”/buy ratings and raises to price targets offset by some downgrades and cuts; consensus is a moderate-buy with an average target ~ $13.25, so analyst views provide both support and caution. MarketBeat analyst summary
• Neutral Sentiment: Valuation write-ups are assessing the stock after recent weakness — useful for longer-term context but not an immediate catalyst. Yahoo Finance article
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent (shows 0 shares/NaN increases), so don’t read too much into those numbers until corrected filings are available.
• Negative Sentiment: Recent quarterly results (Feb. 24) included a large EPS miss (reported -$0.76 vs. consensus $0.34) and slight revenue decline year-over-year — fundamental weakness that has pressured valuation and explains earlier share-price weakness. SEC / MarketBeat filing

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AHCO. Wall Street Zen lowered shares of AdaptHealth from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings downgraded AdaptHealth from a “hold (c-)” rating to a “sell (d)” rating in a report on Wednesday, February 25th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $13.00 price objective on shares of AdaptHealth in a research report on Wednesday, February 25th. Leerink Partners lowered their target price on AdaptHealth from $13.00 to $12.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Finally, Zacks Research upgraded AdaptHealth from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $13.25.

Institutional Investors Weigh In On AdaptHealth

Several large investors have recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new position in shares of AdaptHealth during the third quarter worth $35,000. PNC Financial Services Group Inc. grew its holdings in shares of AdaptHealth by 22.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,003 shares of the company’s stock valued at $70,000 after buying an additional 1,279 shares during the period. Tower Research Capital LLC TRC increased its position in shares of AdaptHealth by 318.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,592 shares of the company’s stock valued at $90,000 after buying an additional 7,297 shares in the last quarter. Tidal Investments LLC acquired a new stake in AdaptHealth during the 2nd quarter worth $96,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in AdaptHealth during the 3rd quarter worth $97,000. Institutional investors own 82.67% of the company’s stock.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.